Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study

Comment

Jøran Hjelmesaeth et al. Lancet. 2002.

. 2002 Jun 22;359(9324):2201-2; author reply 2203-4.

doi: 10.1016/S0140-6736(02)09074-8.

No abstract available

Comment on

Angiotensin blockade for hypertension: a promise fulfilled.
Brunner HR, Gavras H. Brunner HR, et al. Lancet. 2002 Mar 23;359(9311):990-2. doi: 10.1016/S0140-6736(02)08062-5. Lancet. 2002. PMID: 11937175 No abstract available.
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Dahlöf B, et al. Lancet. 2002 Mar 23;359(9311):995-1003. doi: 10.1016/S0140-6736(02)08089-3. Lancet. 2002. PMID: 11937178 Clinical Trial.